# OnCo record paper-nivolumab-hcc-jama-oncol-2020 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-nivolumab-hcc-jama-oncol-2020/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-nivolumab-hcc-jama-oncol-2020" ;
  schema:name "Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial"@en ;
  schema:description "Phase 2 or 3 results paper on Nivolumab in Hepatocellular carcinoma, in JAMA Oncology (2020), one of the most cited Europe PMC records with Nivolumab in its title."@en ;
  schema:url <https://onco.cc/key-papers/paper-nivolumab-hcc-jama-oncol-2020/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1001/jamaoncol.2020.4564>, <https://pubmed.ncbi.nlm.nih.gov/33001135/>, <https://europepmc.org/article/MED/33001135> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1001/jamaoncol.2020.4564> ;
  schema:datePublished "2020"^^xsd:gYear ;
  schema:author "Yau T, Kang YK, Kim TY, et al." ;
  onco:journals <https://onco.cc/journals/jama-oncology/> .